Xmas present for @RaceOncology and @Mason14
Leqvio approved by the FDA.
Gives a perspective of what non-cancer indications / applications an FTO inhibitor could potentially sell for.
- Peaks sales US $2B
- Buyout by Novartis for USD $9.7B in 2020 ( 4.85x peak sales )
- Precision / stratified approach to Cardiovascular diseases with a PCSK9 inhibitor
https://www.novartis.com/news/media...er-cholesterol-and-keep-it-low-two-doses-year
https://www.fiercepharma.com/market...id-pitfalls-amgen-regeneron-pcsk9-cholesterol
Zantrene - Reformulation, page-9
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.66 |
Change
0.050(3.12%) |
Mkt cap ! $273.4M | |||
| Open | High | Low | Value | Volume |
| $1.61 | $1.66 | $1.61 | $30.94K | 18.85K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3048 | $1.64 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.66 | 858 | 1 |
View Market Depth
| Last trade - 10.37am 29/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |